dc.contributor.author | Artunay, Ozgur | |
dc.contributor.author | Yuzbasioglu, Erdal | |
dc.contributor.author | Unal, Mustafa | |
dc.contributor.author | Rasier, Rifat | |
dc.contributor.author | Sengul, Alper | |
dc.contributor.author | Bahcecioglu, Halil | |
dc.date.accessioned | 2019-08-13T12:10:23Z | |
dc.date.accessioned | 2019-08-13T16:04:25Z | |
dc.date.available | 2019-08-13T12:10:23Z | |
dc.date.available | 2019-08-13T16:04:25Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 1080-7683 | |
dc.identifier.issn | 1557-7732 | |
dc.identifier.uri | https://dx.doi.org/10.1089/jop.2009.0146 | |
dc.identifier.uri | http://hdl.handle.net/11446/3298 | |
dc.description | WOS: 000282643800015 | en_US |
dc.description | PubMed ID: 20874499 | en_US |
dc.description.abstract | Purpose: The aim of this study was to compare the efficacy of bimatoprost 0.03% with brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy. Methods: In this prospective, randomized, double-masked study, 195 eyes of 195 consecutive patients who had YAG laser capsulotomy for posterior capsule opacification were recruited. Eyes received either 1 drop of bimatoprost 0.03% (98 patients) or brimonidine 0.2% (97 patients) at 1 h before laser surgery. A masked observer measured IOP by Goldmann applanation tonometry before treatment and after treatment at 1 h, 3 h, 24 h, and 7 days. Inflammation was evaluated after surgery. Formation of cystoid macular edema was assessed by measuring the macular thickness before and after laser surgery. Results: The average peak of postoperative IOP elevation was 2.2 +/- 3.9 mm Hg in the bimatoprost 0.03% and 3.6 +/- 3.1 mm Hg in the brimonidine 0.2% group. The difference was statistically significant (P<0.001). Postoperative IOP elevations of 10 m Hg or more occurred in 1 eye (1.56%) in the bimatoprost 0.03% group and 5 eyes (7.35%) in the brimonidine 0.2%. This difference was statistically significant (P<0.001). Macular edema and anterior chamber reaction were not observed related to bimatoprost. No clinically significant side effects were noted in either group. Conclusions: Our results indicate that prophylactic use of bimatoprost 0.03% is more effective than brimonidine 0.2% in preventing IOP elevation immediately after YAG laser capsulotomy. Bimatoprost 0.03% as a prostamide analog may provide new option for preventing IOP elevation after YAG laser capsulotomy. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MARY ANN LIEBERT, INC | en_US |
dc.identifier.doi | 10.1089/jop.2009.0146 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.title | Bimatoprost 0.03% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Spike Following Neodymium:Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy | en_US |
dc.type | article | en_US |
dc.relation.journal | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.volume | 26 | en_US |
dc.identifier.startpage | 513 | en_US |
dc.identifier.endpage | 517 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Artunay, Ozgur -- Yuzbasioglu, Erdal -- Rasier, Rifat -- Sengul, Alper -- Bahcecioglu, Halil] Istanbul Bilim Univ, Dept Ophthalmol, Istanbul, Turkey -- [Unal, Mustafa] Akdeniz Univ, Dept Ophthalmol, TR-07058 Antalya, Turkey | en_US |